Moderna returns to profit as Q3 revenue rises 29%

Moderna (NASDAQ:MRNA) reported third-quarter 2026 revenue of $1.313 billion, up 29% year over year, and returned to profitability with net income of $162 million after a $200 million loss a year earlier.

The revenue increase accompanied a recovery in vaccine sales, while the company's updated full-year growth forecast reflects an improvement from its previous expectation of up to 10%.

Merck and Moderna's Phase 3 intismeran autogene study, conducted with KEYTRUDA, showed a 42% reduction in the risk of melanoma recurrence or death compared with KEYTRUDA alone, although the norovirus vaccine programme did not meet its early-success criteria.

Moderna reported diluted earnings of $0.38 per share, compared with a loss of $0.51 a year earlier, while cash and investments reached $8 billion following approximately $2.6 billion in net proceeds from convertible financing.

The company also reported expanded vaccine approvals in the United States and Canada, adding to its commercial vaccine portfolio as it develops treatments targeting infectious diseases and cancer.

Moderna develops messenger RNA (mRNA) vaccines and therapeutics, with commercial products targeting COVID-19 and other infectious diseases alongside investigational cancer treatments.